• SU6656 Src Tyrosine Kinases Inhibitor: Protocols & Applicati

  2026-06-22

  SU6656, a selective Src tyrosine kinases inhibitor from APExBIO, is redefining workflows in both cancer research and regenerative medicine. Its dual capacity to enhance megakaryocyte polyploidization and sensitize tumor vasculature to radiotherapy makes it a uniquely versatile tool for advanced laboratories.

• Nintedanib (BIBF 1120): Advanced Insights for ATRX-Deficient

  2026-06-22

  Explore how Nintedanib (BIBF 1120) is revolutionizing research in ATRX-deficient and fibrotic disease models, with a focus on its mechanistic depth and translational strategies. This article delivers actionable, evidence-based guidance for scientists seeking to optimize antiangiogenic assays.

• Evaluating Dicloxacillin’s Intra- and Extracellular Efficacy

  2026-06-21

  This study rigorously compares the intra- and extracellular antibacterial activity of dicloxacillin against Staphylococcus aureus, employing both in vitro macrophage models and a murine peritonitis system. The findings clarify pharmacodynamic predictors of antibiotic efficacy and emphasize the importance of model choice when assessing treatment strategies for persistent S. aureus infections.

• Applied Workflows with Mifepristone (RU486) in Cancer Resear

  2026-06-20

  Mifepristone (RU486) is a versatile tool for dissecting progesterone receptor signaling in oncology and reproductive biology. This article delivers protocol-focused guidance, troubleshooting tips, and advanced use-cases, grounded in peer-reviewed findings and APExBIO’s high-purity reagent platform.

• Mifepristone (RU486): Mechanistic Insight and Translational

  2026-06-19

  This thought-leadership article for translational researchers explores how Mifepristone (RU486)—a high-purity progesterone receptor antagonist—unlocks new possibilities in oncology and reproductive biology. By dissecting its mechanistic depth, validated protocols, and competitive landscape, we provide actionable guidance for designing next-generation experiments and interpreting cross-domain data.

• HyperFluor 488 Goat Anti-Mouse IgG: Precision Detection Tool

  2026-06-19

  The HyperFluor 488 Goat Anti-Mouse IgG (H+L) Antibody is a fluorescently labeled secondary antibody that delivers high specificity and robust signal amplification in immunofluorescence, flow cytometry, and western blotting. Its affinity purification and advanced fluorophore chemistry enable reproducible, low-background detection of mouse immunoglobulins, supporting both routine and advanced research workflows.

• (-)-JQ1: Gold-Standard Negative Control for BET Bromodomain

  2026-06-18

  (-)-JQ1, a stereoisomer of JQ1, is a validated inactive control for BET bromodomain studies. Unlike (+)-JQ1, it exhibits no significant BRD4 interaction, enabling rigorous specificity assessment in epigenetics and cancer biology research.

• BGJ398 (NVP-BGJ398): Precision FGFR Inhibition in Cancer & D

  2026-06-18

  BGJ398 (NVP-BGJ398) stands out as a selective FGFR1/2/3 inhibitor, empowering oncology and developmental biologists to dissect FGFR signaling with nanomolar precision. Its robust performance in both tumor and developmental models, coupled with practical assay versatility, makes it an essential tool for FGFR-driven malignancies research and beyond.

• Bay 11-7821 (BAY 11-7082): Powering Inflammatory Pathway Res

  2026-06-17

  Bay 11-7821 (BAY 11-7082) enables precise, reproducible dissection of the NF-κB and inflammasome pathways in inflammation and cancer studies. This article delivers hands-on protocol tips, troubleshooting guidance, and advanced workflow strategies to maximize reliability for apoptosis and immune signaling research.

• Halazone: Mechanistic Leverage for Translational Innovation

  2026-06-17

  Explore how Halazone’s unique dual mechanism—combining rapid antimicrobial action with neuronal sodium channel modulation—creates new opportunities for translational research. This article provides mechanistic insights, quantitative validation, and strategic guidance for applying Halazone in both water disinfection and neurophysiology, while contextualizing its competitive edge and clinical relevance.

• Tariquidar (XR9576): Elevating Drug Resistance Research Prot

  2026-06-16

  Tariquidar (XR9576) empowers researchers to dissect and overcome P-glycoprotein–mediated chemoresistance in complex tumor microenvironments. This article delivers data-driven workflows, troubleshooting strategies, and advanced protocol enhancements tailored for transporter-mediated drug disposition studies.

• HyperScribe™ T7 Kit: Precision RNA Synthesis for Metabolic R

  2026-06-16

  Explore how the HyperScribe T7 High Yield RNA Synthesis Kit elevates metabolic research through robust RNA synthesis. This article uncovers new technical and biological insights, highlighting applications in mitochondrial regulation and post-translational control.

• Enhanced Yeast Platform for Sensitive TOR Inhibitor Screenin

  2026-06-15

  This study presents a drug-sensitized yeast system that dramatically improves the detection sensitivity for TOR inhibitors, outperforming traditional wild-type strains. The platform enables rapid, cost-efficient identification of mTOR pathway modulators and clarifies the pathway specificity of compounds such as canagliflozin in metabolic research.

• Methyl-β-cyclodextrin: Practical Guidance for Membrane Studi

  2026-06-15

  Methyl-β-cyclodextrin (SKU C6939) is a high-purity reagent designed for selective extraction of cholesterol and specific lipids from cellular membranes, supporting studies of membrane fluidity and lipid raft organization. It is intended strictly for laboratory research workflows, not for diagnostic or clinical use, and its effectiveness depends on precise handling and storage.

• Doxycycline Hyclate: Matrix Metalloproteinases Inhibitor in

  2026-06-14

  Doxycycline hyclate offers robust, validated inhibition of MMP-2 and MMP-9, enabling researchers to dissect blood-brain barrier dynamics and neuroprotection in translational models. Its high solubility and evidence-based dosing make it a versatile asset in both in vitro and in vivo assay development.

552 records 14/37 page Previous Next First page 上5页 1112131415 下5页 Last page